Back to Directory
Abaloparatide
Performance & EndurancePTH analog for osteoporosis treatment that builds bone density.
Key Benefits
- ✓Increases bone density
- ✓Reduces fracture risk
- ✓Builds new bone
- ✓Treats severe osteoporosis
- ✓Anabolic bone effects
Dosing Information
Dosage Range
80 mcg
Frequency
Once daily
Typical Duration
Maximum 18-24 months lifetime
Detailed Protocol
Administered via subcutaneous injection once daily in the thigh or abdomen. Treatment duration limited to 18-24 months lifetime. Prescription required.
About Abaloparatide
Abaloparatide (Tymlos) is a synthetic analog of parathyroid hormone-related protein (PTHrP). It preferentially activates the RG conformation of the PTH1 receptor, resulting in anabolic bone-building effects. FDA-approved for osteoporosis in postmenopausal women at high fracture risk.
Research Notes
FDA-approved in 2017 for postmenopausal osteoporosis. Clinical trials show superior fracture risk reduction compared to placebo. Prescription medication.
Potential Side Effects
- •Hypercalcemia
- •Dizziness
- •Nausea
- •Injection site reactions
- •Palpitations
- •Black box warning for bone tumors in rats
Always consult with a healthcare professional before starting any peptide therapy.